Technological Advantages
HOME
核心技術: Cancer-Associated Fibroblasts (CAFs)

Cancer-Associated Fibroblasts (CAFs)

Stromal cells are an important component of tumor masses, accounting for approximately 30–90% of the cells within tumor tissues.

Cancer-Associated Fibroblasts (CAFs) is the most abundant stromal cells in tumor microenvironment (TME). CAFs interact with tumor cells, immune cells, and vascular cells to influence tumor growth and metastasis. They are not merely “background cells,” but active drivers of tumor progression: promoting tumor proliferation and metastasis, inducing chemotherapy resistance, shaping an immunosuppressive microenvironment, and modifying extracellular matrix (ECM) properties.

Primary CAFs exhibit high variability depending on tumor type and stage. CellBall Biomedical’s R&D strategy aims to achieve the optimal balance between physiological relevance, complexity, consistency and research efficiency. We focus on establishing stable CAF cell lines and co-culturing them with cancer cells to create clinically relevant tumor models, providing drug development teams with a fast and highly accurate testing platform.

Cancer-Associated Fibroblasts (CAFs) Co-Culture Technology Platform Workflow
Technology2 2
Core Advantages

Six Key Advantages

Technology2 3 en

  1. Clinically Relevant Tumor Microenvironment

    Co-culturing tumor organoids or spheroids with cancer-associated fibroblasts (CAFs) simulates the cell-matrix interactions in tumor tissues, closely mimicking the physiological characteristics of tumors in patients.

  2. Tumor Heterogeneity and Drug Resistance

    Tumor cell-only cultures often fail to represent actual situation. The CAFs co-culture model captures TME heterogeneity and clinically observed drug response patterns.

Application Areas

  • Personalized Precision Medicine

    Clinically derived tumor organoid models combined with CAFs enhances the reliability of patient-specific drug response predictions.

  • Anticancer Drug Development

    Provides a more physiologically relevant tumor microenvironment for screening small molecule drugs, targeted therapies, and immunotherapies.

  • Drug Tolerance and Resistance Studies

    Models tumor heterogeneity and CAF-influenced drug resistance mechanisms, aiding in the development of strategies to overcome resistance.

  • Tumor Microenvironment Research

    Enables systematic investigation of CAFs’ roles in tumor progression, immune suppression, and metastasis.

  • Translational Medicine and Preclinical Model Evaluation

    Establishes preclinical models with high clinical relevance, accelerating the translation of research findings into clinical applications.

Target Users

  • Clinical Partner Hospitals and Precision Medicine Institutions

    Utilize patient-derived tumor organoids (PDOs) co-cultured with cancer-associated fibroblasts (CAFs) to recreate a physiologically relevant tumor microenvironment, establishing a highly clinically relevant drug screening platform for personalized drug response prediction and clinical decision support.

  • New Drug Development Companies

    Provide preclinical cell models that closely mimic clinical tumors for screening and validating anticancer drugs, immunotherapies, and targeted therapies.

  • Translational Medicine Research Units

    Study the key roles of the tumor microenvironment, uncovering its impact on tumor progression, metastasis, and immune suppression, supporting the development of novel therapies.

  • Academic Research Teams

    Focus on fundamental research in tumor biology, tumor-stroma interactions, and drug resistance mechanisms.

Technical Value

The co-culture model of tumor organoids or spheroids with cancer-associated fibroblasts (CAFs) faithfully recreates the clinical tumor microenvironment in a 3D setting, capturing cell-cell and cell-matrix interactions that influence tumor proliferation, invasion, and drug resistance.

This model not only enhances the clinical relevance of drug screening and supports personalized precision medicine strategies, but also serves as a platform for studying tumor-stroma interactions and resistance mechanisms. It combines scientific research and commercial value, making it a critical technology platform for new drug development, preclinical evaluation, and precision medicine applications.